Inotuzumab ozogamicin - Pfizer

Drug Profile

Inotuzumab ozogamicin - Pfizer

Alternative Names: Besponsa; CMC-544; PF-5208773; WAY-207294

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech Group
  • Developer Alliance for Clinical Trials in Oncology; Cancer Research UK; Case Comprehensive Cancer Center; Children's Oncology Group; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; SWOG; University College London; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cytostatic antibiotics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action CD22 antigen inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Chronic myeloid leukaemia
  • No development reported Acute biphenotypic leukaemia; Burkitt's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Feb 2018 Launched for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in USA (IV) (NCT03441061), before February 2018 - First global launch
  • 15 Feb 2018 M.D. Anderson Cancer Center and Pfizer initiates enrolment in a phase II trial for Precursor-cell-lymphoblastic-leukaemia-lymphoma (Second line therapy or greater) in USA (NCT03441061)
  • 19 Jan 2018 Registered for Acute lymphoblastic leukaemia (Second-line therapy or greater) in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top